X0303 4 2009-09-14 0 0001367644 Emergent BioSolutions Inc. EBS 0001380185 El-Hibri Fuad 2273 RESEARCH BLVD, SUITE 400 ROCKVILLE MD 20850 1 1 1 0 CEO & Chairman Common Stock 2009-09-14 4 M 0 37700 3.50 A 975119 D Common Stock 2009-09-14 4 S 0 37700 19.26 D 937419 D Common Stock 2009-09-15 4 M 0 16270 3.50 A 953689 D Common Stock 2009-09-15 4 M 0 54000 10.13 A 1007689 D Common Stock 2009-09-15 4 M 0 3730 7.00 A 1011419 D Common Stock 2009-09-15 4 S 0 74000 19.67 D 937419 D Common Stock 2009-09-16 4 M 0 29604 7.00 A 967023 D Common Stock 2009-09-16 4 S 0 50000 19.84 D 917023 D Common Stock 5011 I By Karim El-Hibri Trust Common Stock 5011 I By Yusra El-Hibri Trust Common Stock 5011 I By Faiza El-Hibri Trust Common Stock 7181835 I By Intervac, L.L.C. Common Stock 2965043 I By BioPharm, L.L.C. Common Stock 1599155 I By Biovac, L.L.C. Employee Stock Option (right to buy) 3.50 2009-09-14 4 M 0 37700 0 D 2008-01-01 2010-05-25 Common Stock 37700 102582 D Employee Stock Option (right to buy) 3.50 2009-09-15 4 M 0 16270 0 D 2008-01-01 2010-05-25 Common Stock 16270 86312 D Employee Stock Option (right to buy) 10.13 2009-09-15 4 M 0 54000 0 D 2013-12-12 Common Stock 54000 27000 D Employee Stock Option (right to buy) 7.00 2009-09-15 4 M 0 3730 0 D 2015-03-10 Common Stock 3730 96270 D Employee Stock Option (right to buy) 7.00 2009-09-16 4 M 0 29604 0 D 2015-03-10 Common Stock 29604 66666 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2009, as modified on August 11, 2009. This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $19.09 to $19.36. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $19.40 to $19.85. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $19.80 to $19.91. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. These shares are held in a trust for the benefit of a child of the reporting person. The reporting person is trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Mr. El-Hibri holds, individually and with his wife, as tenants by the entirety, an aggregate 38.0276% equity interest in Intervac, L.L.C. Intervac, L.L.C. is the direct owner of 7,181,835 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Intervac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest therein in 2,731,079 shares. Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 2,965,043 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,191,057 shares. Mr. El-Hibri holds with his wife, as tenants by the entirety, a 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,599,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,426,446 shares. The option vests in three equal installments on December 12, 2007, December 12, 2008 and December 12, 2009. The option vests in three equal installments on March 11, 2009, March 11, 2010 and March 11, 2011. /s/ Carl A. Valenstein, attorney-in-fact 2009-09-16